Lifshitz & Miller LLP Announces Investigation of Alere Inc., Emergent BioSolutions, Inc., Frontier Communications Corporation, HSN, Inc., Insys Therapeutics Inc., LSB Industries, Inc. and Otonomy,

Frontier Communications Corporation (FTR)

Lifshitz & Miller announces an investigation on behalf of FTR investors concerning whether FTR failed to disclose that it acquired a substantial number of non-paying accounts when it acquired the wireline operations of Verizon Communications, Inc.  As a result, FTR would increase its reserves, and write off amounts from accounts receivable associated with the non-paying accounts.

If you are an FTR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

HSN, Inc. (HSNI)

Lifshitz & Miller announces an investigation into possible breaches of fiduciary duties by the board of directors of HSNI in connection with the sale of HSNI to Liberty Interactive Corporation, QVC's parent company, for 1.65 shares of Series A of QVC Group for each share of HSNI owned.

If you are an HSNI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Insys Therapeutics Inc. (INSY)

Lifshitz & Miller announces that on August 1, 2017, the U.S. District Court for the District of Arizona denied INSY's motion to dismiss a putative class action against INSY, among others.

If you are an INSY investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

LSB Industries, Inc. (LXU)

Lifshitz & Miller announces that on March 2, 2017, the U.S. District Court for the Southern District of New York denied LXU's motion to dismiss a putative class action against LXU, among others.

If you are an LXU investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Otonomy, Inc. (OTIC)

Lifshitz & Miller announces an investigation on behalf of OTIC investors concerning whether OTIC issued false and misleading statements about its phase 3 clinical trial of OTIVIDEX.

If you are an OTIC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

ATTORNEY ADVERTISING. © 2017 Lifshitz & Miller LLP.  The law firm responsible for this advertisement is Lifshitz & Miller LLP, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz & Miller LLP
Phone:  516-493-9780 
Facsimile: 516-280-7376
Email: info@jlclasslaw.com

View original content:http://www.prnewswire.com/news-releases/lifshitz--miller-llp-announces-investigation-of-alere-inc-emergent-biosolutions-inc-frontier-communications-corporation-hsn-inc-insys-therapeutics-inc-lsb-industries-inc-and-otonomy-inc-300530414.html

SOURCE Lifshitz & Miller Law Firm